Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study

Abstract

Mycosis Fungoides (MF) is a rare T-cell lymphoma and evidence on treatment practices, and outcomes are limited. We evaluated changes in practice patterns and corresponding effects on overall survival (OS) in MF using a cross-sectional study of patients diagnosed with MF from 2004 to 2016 in the National Cancer Database. Outcomes evaluated included patterns of care and OS across treatment eras. We found factors associated with chemotherapy use included male gender, treatment from 2004 to 2010 and stage III-IV disease. Factors associated with radiotherapy receipt included stage I-II disease, nonacademic treatment centers, male gender, non-black race, and Medicare status. Immunotherapy use was associated with treatment from 2004 to 2010 and stage III-IV disease. After propensity score matching, there was no OS difference among patients with stage I-II disease between 2004–2010 and 2011–2016. However, amongst patients with stage III-IV disease, OS was significantly improved in those treated from 2011 to 2016.

Keywords:

• Mycosis fungoides
• radiotherapy
• chemotherapy
• immunotherapy
• overall survival
• patterns of care

Disclosure statement

No potential conflict of interest was reported by the author(s).